Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
A monthly subcutaneous injection of 70 mg erenumab may represent an effective prophylactic treatment for episodic migraine.
A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
Pain experienced by patients during episodic migraine is associated with the occurrence of white matter hyperintensities in the cerebral hemisphere ipsilateral to the pain side.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.
A large proportion of patients with episodic migraine have greater risk for cardiovascular disease with increasing age and subsequently have contraindications to treatment with triptan and ergot medications.
A recently published case series describes a new subtype of chronic daily headache that appears to be associated with elevated cerebrospinal fluid pressure.
Among individuals diagnosed with episodic migraines, stressful events can accurately predict an individual's risk of a headache, even before the onset of prodromal symptoms.
Examination of hypothalamic activity shows distinctly different patterns between episodic and chronic forms of migraine.
In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.
Frequent Headache, Depression, and Medication Overuse Have Negative Impact on Treatments for Episodic MigraineJune 10, 2016
Effectiveness of an Anti-CGRP Antibody in Enhancing Wellness During Migraines' Prodrome and Postdrome PhasesJune 10, 2016
Anti-CGRP Antibody for Migraine
Clinical Pain Advisor Articles
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Factors Associated With Neuropathic Pain in Ankylosing Spondylitis
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Recommendations Developed for Managing Postpartum Pain
- Cryoablation Efficacious for Cancer Pain, Review Finds
- Art Intervention Clinically Effective in Treating Cancer-Related Pain, Mood Symptoms
- Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression
- PTSD Symptoms and the Acute Pain Response in Low-Income Women